N,N- dicyclohexylamide- N'- (3- diethylaminopropyl)- N- (N- nitrobenzoyl) aminoacetic acid hydroxyoxalate

an antiarrhythmia agents

Also Known As:

cardiocyclide

Networked: 6 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclohexanes: 3
        N,N-dicyclohexylamide-N'-(3-diethylaminopropyl)-N-(N-nitrobenzoyl) aminoacetic acid hydroxyoxalate: 6
- Carboxylic Acids: 973
  - Acyclic Acids
    - Acetates: 4994
      - N,N-dicyclohexylamide-N'-(3-diethylaminopropyl)-N-(N-nitrobenzoyl) aminoacetic acid hydroxyoxalate: 6
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Acetates: 4994
      - N,N-dicyclohexylamide-N'-(3-diethylaminopropyl)-N-(N-nitrobenzoyl) aminoacetic acid hydroxyoxalate: 6

Experts

1.	Kaverina, N V: 4 articles (01/2007 - 03/2002)
2.	Popova, E P: 3 articles (01/2007 - 01/2003)
3.	Kryzhanovskiĭ, S A: 2 articles (01/2010 - 03/2002)
4.	Vititnova, M B: 2 articles (01/2010 - 03/2002)
5.	Lyskovtsev, V V: 2 articles (01/2007 - 01/2003)
6.	Stoliaruk, V N: 1 article (01/2010)
7.	Tsorin, I B: 1 article (01/2010)
8.	Chichkanov, G G: 1 article (03/2003)

Related Diseases

1.	Atrial Fibrillation 01/01/2010 - "When administered to cats with vagotonic atrial fibrillation afobasol (7.5 mg/kg v/v) exhibited anti-arrhythmic activity at least as high as that of class 1 and III anti-arrhythmic agents (etacisin and cardiocyclide respectively) (Vaughan Williams classification). " 01/01/2007 - "Cardiocyclide was injected in a dose of 2.5-5.0 mg/kg; nibentan, 0.25 mg/kg; and sotalol, 2.5 mg/kg. Cardiocyclide was found to prevent vagotonic atrial fibrillation in 80% of cases; under vagal stimulation this drug maintained the electrophysiological attributes and exhibited the frequency-independent action inherent in this agent. " 01/01/2007 - "The electrophysiological properties of cardiocyclide, nibentan and sotalol and their efficacy on a model of atrial fibrillation were compared in experiments in anaesthetized dogs. " 01/01/2007 - "[Comparative study of the electrophysiological properties of class iii medicinals (cardiocyclide, nibentan, sotalol) and evaluation of their efficacy in atrial fibrillation produced by auricular and vagal stimulation]."
2.	Myocardial Ischemia (Ischemic Heart Diseases) 03/01/2002 - "[Comparative study of the anti-arrhythmic activity of cardiocyclide and nibentan in hypersympathotonia and acute myocardial ischemia]."
3.	Tachycardia (Tachyarrhythmias) 03/01/2003 - "Cardiocyclide is a class III antiarrhythmic drug, producing a frequency-independent action; is a promising agent for the treatment of dangerous tachyarrhythmias. "
4.	Myocardial Infarction 01/01/2003 - "Electrophysiological mechanisms of the action of cardiocyclide, nibentan, and sotalol--antiarrhythmic agents of class III--was studied in dogs with experimental myocardial infarction induced by a two-step occlusion of the coronary artery. " 01/01/2003 - "[Comparative study of electrophysiological mechanisms of anti-arrhythmia III class agents, cardiocyclide, nibentan, and sotalol during experimental myocardial infarction and sympathetic stimulation]."
5.	Bradycardia 07/01/2005 - "Sotalol is less effective than cardiocyclide in the case of vagotonic atrial stimulation and does not prevent the bradycardia induced by the vagus nerve excitation. "

Related Drugs and Biologics

1.	Sotalol (Sotalol Hydrochloride)
2.	Anti-Arrhythmia Agents
3.	nibentan (HE 11)